+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-12-16Number of Pages: 224

Neurological Disorder Drugs Market (Disorder - Epilepsy, Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, and Cerebrovascular Disease; Drug Type - Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, and Anticoagulants; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and eCommerce) - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Europe Neurological Disorders Drugs Market: Snapshot

Neurological drugs are developed to treat neurological disorders such as epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, schizophrenia, traumatic brain injury, spinal cord injury, cerebrovascular diseases, and others. The growing prevalence of these disorders across the European region is anticipated to drive the demand for neurological disorder drugs market in the coming few years. The research report projects that intensifying concerns about living an adjusted life have prompted several patients to seek help. According to the study, the Europe neurological disorder drugs market was valued is expected to reach a valuation of US$32.0 bn by the end of 2024 as compared to US$18.3 bn in 2015. During the forecast years of 2016 and 2024, the overall market is expected to surge at a CAGR of CAGR of 6.4%.

neurological disorder drugs market

Increasing Research and Development Fuels Market Growth

The Europe neurological disorders drugs market will be fueled by the growing initiatives taken by governments of several countries to educate the masses and to develop new drugs. For instance, European Parkinson's Disease Association in Europe is offering affordable medications to patients, campaigning to raise awareness, and supporting research and development activities to drive the overall neurological disorder drugs market. The market has also seen a steady emergence of several research and development programs that are focused toward developing effective drugs that come at affordable prices. The collective rise in the spending of countries on developing neurological disorder drugs is expected to improve the market’s revenue in the coming few years.

On the basis of various disorders, the market caters to disorders such as epilepsy, Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, cerebrovascular disease and others. Out of all of these segments, the cerebrovascular disease held the dominant share in terms of revenue in 2015. The World Health Organization (WHO) states that the cerebrovascular diseases, which can manifest as a stroke, migraine and headache is the common cause of worry for several patients. About 80% of the patients suffering from cerebrovascular diseases across EU% show these symptoms. Thus, this segment is expected to exhibit a robust growth rate in the coming few years.

Germany Stands out as Highest Consumer of Neurological Disorder Drugs in Europe

In terms of geography, the Europe neurological disorder drugs market is segmented into Germany, France, Italy, Spain, U.K., Russia, Netherlands, Switzerland, Poland, and Rest of Europe. The research report states that Germany held a significant share in the market in 2015, closely followed by France. The regions will dominate over the forecast period due to the rising prevalence of neurological disorders and improving the awareness about the diseases due to support groups and government initiatives. Furthermore, the rising pool of geriatrics in Germany will also boost the uptake of neurological disorders drugs in the coming few years.

Presently, Germany, the U.K., France, Switzerland, Italy, and Spain are the leading countries in Europe in the neurological disorder drugs market. The study indicates that Switzerland will offer several growth opportunities to the overall market as awareness about these life-altering diseases grows.

The leading players operating in the Europe neurological disorders market are Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, and GlaxoSmithKline plc. Among these, Merck & Co., GlaxoSmithKline plc and Novartis AG. The research report states that the market is consolidated due to the presence of several small players in who hold significant share in the market. Most of these companies are focusing on improving their pipelines and expanding their geographical outreach to retain their dominance.

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Assumptions and Acronyms Used
1.3 Research Methodology

Section 2 Market Overview
2.1 Executive Summary
2.2 Market Snapshot

Section 3 Market Dynamics
3.1 Drivers and Restraints Snapshot Analysis
3.2 Drivers
      3.2.1 Aging population leading to increase neurological disorders
      3.2.2 Increasing Therapeutic Treatments
      3.2.3 Rise in interventions by government bodies
      3.2.4 Rising Research & Development Programmes
      3.2.5 Spending on neurological drugs to grow in developing countries
      3.2.6 Growing awareness among people
3.3 Restraints
      3.3.1 High treatment cost
      3.3.2 Stringent regulations
3.4 Opportunities
      3.5.1 Technological Advancement and Innovation
      3.5.2 Significant Scope in Emerging Markets

Section 4 Market Overview
4.1 Europe Neurological Disorder Drugs Market Analysis and Forecasts, Market Revenue Projections (US$ Mn)
4.2 Disease description and epidemiology
      4.2.1 Muscle Dystrophy
      4.2.2 Multiple Sclerosis
      4.2.3 Parkinson Disease
      4.2.4 Amputees
4.3 Disease Frequency by Country
4.4 Future Outlook
4.5 Target population by Age Group
4.6 Alzheimer Disease - Prevalence Rate
4.7 Living Conditions
4.8 Neurological Disorder Drugs Market Outlook

Section 5 Europe Neurological Disorder Drugs Market Analysis, by Disorder
5.1 Introduction
5.2 Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Disorder
5.3 Europe Neurological Disorder Drugs Market Forecast, by Disorder
      5.3.1 Epilepsy
      5.3.2 Alzheimer’s Disease
      5.3.3 Parkinson Disease
      5.3.4 Multiple Sclerosis
      5.3.5 Cerebrovascular Disease
      5.3.6 Others

Section 6 Europe Neurological Disorder Drugs Market Analysis, by Drug Type
6.1 Introduction
6.2 Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Drug Type
6.3 Europe Neurological Disorder Drugs Market Forecast, by Drug Type
      6.3.1 Anticholinergic
      6.3.2 Antiepileptic
      6.3.3 Antipsychotic
      6.3.4 Analgesics
      6.3.5 Hypnotic & Sedative
      6.3.6 Antihypertensive
      6.3.7 Anticoagulants
      6.3.8 Others

Section 7 Europe Neurological Disorder Drugs Market Analysis, by Distribution Channel
7.1 Introduction
7.2 Europe Neurological Disorder Drugs Market Value Share and Attractiveness Analysis, by Distribution Channel
7.3 Europe Neurological Disorder Drugs Market Forecast, by Distribution Channel
      7.3.1 Hospital Pharmacy
      7.3.2 Retail Pharmacy
      7.3.3 eCommerce

Section 8 Europe Neurological Disorder Drugs Market Analysis By Country
8.1 Neurological Disorder Drugs Market Forecast, By Country

Section 9 Germany Neurological Disorder Drugs Market Analysis
9.1 Germany Neurological Disorder Drugs Market Overview
9.2 Germany Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
9.3 Germany Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
9.4 Disease description and epidemiology
      9.4.1 Muscular Dystrophy
      9.4.2 Multiple Sclerosis
      9.4.3 Parkinson’s Disease
      9.4.4 Amputees
9.5 Disease Frequency by Country
9.6 Target population by Age Group
9.7 Alzheimer's Disease – Prevalence Rate
9.8 Living Conditions

Section 10 UK Neurological Disorder Drugs Market Analysis
10.1 UK Neurological Disorder Drugs Market Overview
10.2 UK Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
10.3 UK Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
10.4 Disease description and epidemiology
      10.4.1 Muscular Dystrophy
      10.4.2 Multiple Sclerosis
      10.4.3 Parkinson’s Disease
      10.4.4 Amputees
      10.4.5 Disease Cost
10.5 Target population by Age Group
10.6 Alzheimer's Disease – Prevalence Rate
10.7 Living Conditions

Section 11 France Neurological Disorder Drugs Market Analysis
11.1 France Neurological Disorder Drugs Market Overview
11.2 France Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
11.3 France Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
11.4 Disease description and epidemiology
      11.4.1 Muscular Dystrophy
      11.4.2 Multiple Sclerosis
      11.4.3 Factors Associated with Increased Risk for Multiple Sclerosis
      11.4.4 Parkinson’s Disease
      11.4.5 Amputees
11.5 Disease Cost
11.6 Target population by Age Group
11.7 Alzheimer's Disease – Prevalence Rate
11.8 Living Conditions

Section 12 Italy Neurological Disorder Drugs Market Analysis
12.1 Italy Neurological Disorder Drugs Market Overview
12.2 Italy Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
12.3 Italy Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
12.4 Disease description and epidemiology
      12.4.1 Muscular Dystrophy
      12.4.2 Multiple Sclerosis
      12.4.3 Parkinson’s Disease
      12.4.4 Amputees
12.5 Disease Frequency
12.6 Target population by Age Group
12.7 Alzheimer's Disease – Prevalence Rate
12.8 Disability – Targeted Age Group 
12.9 Living Conditions

Section 13 Spain Neurological Disorder Drugs Market Analysis
13.1 Spain Neurological Disorder Drugs Market Overview
13.2 Spain Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
13.3 Spain Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
13.4 Disease description and epidemiology
      13.4.1 Muscular Dystrophy
      13.4.2 Multiple Sclerosis
      13.4.3 Parkinson’s Disease
      13.4.4 Amputees
13.5 Target population by Age Group
13.6 Alzheimer's Disease – Targeted Age Group
13.7 Living Conditions

Section 14 Russia Neurological Disorder Drugs Market Analysis
14.1 Russia Neurological Disorder Drugs Market Overview
14.2 Russia Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
14.3 Russia Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
14.4 Disease description and epidemiology
      14.4.1 Muscular Dystrophy
      14.4.2 Multiple Sclerosis
      14.4.3 Parkinson’s Disease
      14.4.4 Amputees
14.5 Target population by Age Group
14.6 Living Conditions

Section 15 Netherlands Neurological Disorder Drugs Market Analysis
15.1 Netherlands Neurological Disorder Drugs Market Overview
15.2 Netherlands Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
15.3 Netherlands Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
15.4 Disease description and epidemiology
      15.4.1 Muscular Dystrophy
      15.4.2 Multiple Sclerosis
      15.4.3 Parkinson’s Disease
      15.4.4 Amputees
15.5 Disease Cost
15.6 Target population by Age Group
15.7 Alzheimer's Disease – Prevalence Rate
15.8 Living Conditions

Section 16 Switzerland Neurological Disorder Drugs Market Analysis
16.1 Switzerland Neurological Disorder Drugs Market Overview
16.2 Switzerland Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
16.3 Switzerland Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
16.4 Disease description and epidemiology
      16.4.1 Muscular Dystrophy
      16.4.2 Multiple Sclerosis
      16.4.3 Parkinson’s Disease
      16.4.4 Amputees
16.5 Disease Cost
16.6 Target population by Age Group
16.7 Alzheimer's Disease – Prevalence Rate
16.8 Living Conditions

Section 17 Poland Neurological Disorder Drugs Market Analysis
17.1 Poland Neurological Disorder Drugs Market Overview
17.2 Poland Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
17.3 Poland Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
17.4 Disease description and epidemiology
      17.4.1 Muscular Dystrophy
      17.4.2 Multiple Sclerosis
      17.4.3 Parkinson’s Disease
      17.4.4 Amputees
17.5 Target population by Age Group
17.6 Alzheimer's Disease – Targeted Age Group
17.7 Alzheimer's Disease – Prevalence Rate
17.8 Living Conditions

Section 18 Rest of Europe Neurological Disorder Drugs Market Analysis
18.1 Rest of Europe Neurological Disorder Drugs Market Overview
18.2 Rest of Europe Market Value Share Analysis, By Disorder, Drug Type and Distribution channel
18.3 Rest of Europe Market Attractiveness Analysis, By Disorder, Drug Type and Distribution channel
18.4 Disease description and epidemiology
      18.4.1 Muscular Dystrophy
      18.4.2 Multiple Sclerosis
      18.4.3 Parkinson’s Disease
      18.4.4 Amputees
18.5 Alzheimer's Disease – Prevalence Rate
18.6 Living Conditions

Section 19 Company Profiles
19.1 Neurological Disorder Drugs Market Share Analysis, by Company (2015)
19.2 Company profiles
      19.2.1 Novartis AG
               19.2.1.1. Company Overview
               19.2.1.2. Business Overview
               19.2.1.3. Financial Overview
               19.2.1.4. SWOT Analysis
               19.2.1.5. Strategic Overview
      19.2.2 GlaxoSmithKline plc
               19.2.2.1. Company Overview
               19.2.2.2. Business Overview
               19.2.2.3. Financial Overview
               19.2.2.4. SWOT Analysis
               19.2.2.5. Strategic Overview      
      19.2.3 Merck & Co.
               19.2.3.1. Company Overview
               19.2.3.2. Business Overview
               19.2.3.3. Financial Overview
               19.2.3.4. SWOT Analysis
               19.2.3.5. Strategic Overview
      19.2.4 Bayer AG
               19.2.4.1. Company Overview
               19.2.4.2. Business Overview
               19.2.4.3. Financial Overview
               19.2.4.4. SWOT Analysis
               19.2.4.5. Strategic Overview
      19.2.5 AstraZeneca
               19.2.5.1. Company Overview
               19.2.5.2. Business Overview
               19.2.5.3. Financial Overview
               19.2.5.4. SWOT Analysis
               19.2.5.5. Strategic Overview
      19.2.6 Boehringer Ingelheim GmbH
               19.2.6.1. Company Overview
               19.2.6.2. Business Overview
               19.2.6.3. Financial Overview
               19.2.6.4. SWOT Analysis
               19.2.6.5. Strategic Overview
      19.2.7 Teva Pharmaceutical Industries Ltd.
               19.2.7.1. Company Overview
               19.2.7.2. Business Overview
               19.2.7.3. Financial Overview
               19.2.7.4. SWOT Analysis
               19.2.7.5. Strategic Overview
      19.2.8 F. Hoffmann-La Roche Ltd.
               19.2.8.1. Company Overview
               19.2.8.2. Business Overview
               19.2.8.3. Financial Overview
               19.2.8.4. SWOT Analysis
               19.2.8.5. Strategic Overview

List of Figures

Figure 01: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2015–2024 
Figure 02: Europe Neurological Disorder Drugs Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 03: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Disorder, 2015
Figure 04: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 05: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 06: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 07: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 08: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 10: Europe Neurological Disorder Drugs Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 11: Neurological Disorder Drugs Market Attractiveness Analysis, by Drug Type
Figure 12: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 13: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 14: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 15: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 16: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 17: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 18: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 19: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 20: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 21: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024 
Figure 22: Europe Neurological Disorder Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 23: Europe Neurological Disorder Drugs Market Attractiveness Analysis, by Distribution channel, 2015
Figure 24: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2014–2024 
Figure 25: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2014–2024 
Figure 26: Europe Neurological Disorder Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2014–2024 
Figure 27: Europe Neurological Disorder Drugs Market Value Share Analysis, by Country Type, 2016 and 2024 
Figure 28: Neurological Disorder Drugs Market Attractiveness Analysis, by Region Type
Figure 29: Germany Neurological Disorder Drugs Market Size
Figure 30: Germany Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 31: Germany Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 32: Germany Market Value Share Analysis, by Drug Type, 2016 and 2024
Figure 33: Germany Market Value Share Analysis, by Distribution channel, 2016 and 2024 
Figure 34: U.K. Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 35: U.K. Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 36: U.K. Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 37: U.K. Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 38: U.K. Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 39: France Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 40: France Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 41: France Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 42: France Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 43: France Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 44: Italy Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 45: Italy Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 46: Italy Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 47: Italy Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 48: Italy Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 49: Spain Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 50: Spain Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 51: Spain Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 52: Spain Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 53: Spain Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 54: Russia Neurological Disorder Drugs Market Size
Figure 55: Russia Neurological Disorder Drugs Market Size Y-o-Y Growth Projections, 2015–2024
Figure 56: Russia Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 57: Russia Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 58: Russia Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 59: Netherlands Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 60: Netherlands Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 61: Netherlands Market Value Share Analysis, by Disorder, 2016 and 2024
Figure 62: Netherlands Market Value Share Analysis, by Drug Type, 2016 and 2024
Figure 63: Netherlands Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 64: Switzerland Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 65: Switzerland Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 66: Switzerland Market Value Share Analysis, by Disorder, 2016 and 2024
Figure 67: Switzerland Market Value Share Analysis, by Drug Type, 2016 and 2024
Figure 68: Switzerland Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 69: Poland Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 70: Poland Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 71: Poland Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 72: Poland Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 73: Poland Market Value Share Analysis, by Distribution Channel, 2016 and 2024 
Figure 74: Rest of Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, 2014–2024 
Figure 75: Rest of Europe Neurological Disorder Drugs Market Size Y-o-Y Growth Projections (%), 2015–2024
Figure 76: Rest of Europe Market Value Share Analysis, by Disorder, 2016 and 2024 
Figure 77: Rest of Europe Market Value Share Analysis, by Drug Type, 2016 and 2024 
Figure 78: Rest of Europe Market Value Share Analysis, by Distribution Channel, 2016 and 2024

List of Tables

Table 01: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Disorder, 2014–2024 
Table 02: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2014–2024 
Table 03: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024 
Table 04: Europe Neurological Disorder Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024

Europe Neurological Disorder Drugs Market: Overview

This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related to life threatening diseases are the major concerns in the developed and developing countries of Europe.

This research report provides a detailed analysis of the neurological disorder drugs market and helps understand the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. Market dynamics factors such as market attractiveness analysis have also been explained in order to deliver a thorough analysis of the overall competitive scenario of the Europe neurological disorder drugs market.

Europe Neurological Disorder Drugs Market: Segmentation

The neurological disorder drugs market has been segmented by disorder, by drug class, by distribution channel and by countries. The disorder segment has been sub-segmented into Epilepsy, Parkinson’s disease, Alzheimer’s disease, Multiple Sclerosis, Cerebrovascular disease and others. The drug class has been segmented into Anticholinergic, Antiepileptic, Antipsychotic, Analgesics, Hypnotic & Sedative, Antihypertensive, Anticoagulants and others. The distribution channel segment has been sub-segments into retail pharmacy, hospital pharmacy and eCommerce.

Europe Neurological Disorder Drugs Market: Scope

The executive summary provides detailed insights about the report and the market in general. This elaborate executive summary provides a glimpse into the present scenario of the Europe neurological disorder drugs market, which includes a market snapshot that provides overall information of various segments and sub-segments. The executive summary also provides overall information and data analysis of the Europe neurological disorder drugs market with respect to market segments based on disorder, drug class, distribution channel as well as geographic regions.

The market for neurological disorder drugs has been extensively analyzed based on their usefulness, effectiveness, sales revenue and geographic presence. The market size and forecast in terms of US$ Mn for each disorder, drug class, distribution channel as well as geographic regions has been provided for the period from 2016 to 2024. This report on the neurological disorder drugs market also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2016 to 2024, considering 2015 as the base year.

Europe Neurological Disorder Drugs Market: Regional Outlook

Geographically, the neurological disorder drugs market has been segmented into 10 major regions: Germany, France, Italy, Spain, U.K., Russia, Switzerland, Netherlands, Poland and Rest of Europe. The market size and forecast for each of these regions have been provided for the period from 2016 to 2024, along with CAGR (%) for the forecast period from 2016 to 2024. The research study also incorporates the competitive scenario in these regions.

Key Players Mentioned in this Report are:

A list of recommendations has been provided for new entrants as well as existing players to help establish a strong presence in the market and increase market share. The report also profiles major players in the neurological disorder drugs market based on various attributes such as company overview, financial overview, business strategies, product portfolio and recent developments. Major players profiled in this report include Merck & Co., Boehringer Ingelheim GmbH, Bayer AG, Astra Zeneca, F-Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, and GlaxoSmithKline plc.

The Europe Neurological Disorder Drugs market is segmented as follows:

  • Europe Neurological Disorder Drugs Market Revenue, by Disorder
    • Epilepsy
    • Alzheimer’s disease
    • Parkinson’s disease
    • Multiple Sclerosis
    • Cerebrovascular disease
    • Others
       
  • Europe Neurological Disorder Drugs Market Revenue, by Drug Class
    • Anticholinergic
    • Antiepileptic
    • Antipsychotic
    • Hypnotic & Sedative
    • Analgesics
    • Antihypertensive
    • Anticoagulants
    • Others
       
  • Europe Neurological Disorder Drugs Market Revenue, by Distribution Channel
    • Retail Pharmacy
    • Hospital Pharmacy
    • eCommerce
       
  • Europe Neurological Disorder Drugs Market Revenue, by Geography
    • Germany
    • France
    • Italy
    • Spain
    • UK
    • Russia
    • Switzerland
    • Netherlands
    • Poland
    • Rest of Europe


 
 
Back To Top